Please ensure Javascript is enabled for purposes of website accessibility

Bristol Myers Squibb Wins FDA Approval for Leukemia Drug

By Eric Volkman – Sep 1, 2020 at 11:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Onureg is aimed at treating a particularly aggressive form of the disease.

While the world awaits treatments and vaccines targeting the SARS-CoV-2 coronavirus still ravaging the world, drug developers and regulators are getting on with other business. One illustration of this occurred on Tuesday, when the Food and Drug Administration granted approval to Bristol Myers Squibb (BMY 0.96%) for its Onureg leukemia drug.

Onureg was given the green light for, in the company's words "the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy and who are not able to complete intensive curative therapy." The medication is administered orally, once per day.

Red blood cells.

Image source: Getty Images.

AML is an aggressive blood and bone marrow cancer in which the body produces abnormal myeloblasts, platelets, or red blood cells. Myeloblasts are a form of white blood cell. According to Bristol Myers Squibb, AML is one of the most common types of acute leukemias in adults.

"This milestone is representative of our commitment to helping patients with hard-to-treat cancers live longer, and the approval of Onureg as an oral therapy option for patients is more relevant now than ever as the world continues to navigate the COVID-19 pandemic," the company quoted its CEO Giovanni Caforio as saying.

Onureg had a long development path. It is the product of more than 10 years of research, and it underwent a total of 13 pre-clinical and clinical trials.

In May, Bristol Myers Squibb filed a Marketing Authorization Application to the European Union's European Medicines Agency for the same indication. It is currently under review.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$71.21 (0.96%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.